EP0719132A1 - Procede et composition de soin pour la peau - Google Patents

Procede et composition de soin pour la peau

Info

Publication number
EP0719132A1
EP0719132A1 EP94926925A EP94926925A EP0719132A1 EP 0719132 A1 EP0719132 A1 EP 0719132A1 EP 94926925 A EP94926925 A EP 94926925A EP 94926925 A EP94926925 A EP 94926925A EP 0719132 A1 EP0719132 A1 EP 0719132A1
Authority
EP
European Patent Office
Prior art keywords
composition
cathepsin
acid
stratum corneum
enzyme
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP94926925A
Other languages
German (de)
English (en)
Inventor
Anthony Vincent Rawlings
Allan Watkinson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Unilever PLC
Unilever NV
Original Assignee
Unilever PLC
Unilever NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Unilever PLC, Unilever NV filed Critical Unilever PLC
Publication of EP0719132A1 publication Critical patent/EP0719132A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/006—Antidandruff preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/488—Aspartic endopeptidases (3.4.23), e.g. pepsin, chymosin, renin, cathepsin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/007—Preparations for dry skin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6427—Chymotrypsins (3.4.21.1; 3.4.21.2); Trypsin (3.4.21.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/23—Aspartic endopeptidases (3.4.23)
    • C12Y304/23005—Cathepsin D (3.4.23.5)

Definitions

  • the present invention relates to compositions for application to the skin and their cosmetic and/or pharmaceutical use.
  • the invention relates to compositions comprising stratum comeum cathepsin-D-like enzymes and their use in alleviating or preventing conditions involving abnormal desquamation by facilitating desmosomal degradtion.
  • SCE serine protease stratum corneum chy otryptic-like enzyme
  • stratum corneum cathepsin-D-like enzymes which may be involved in the process of cell dissociation (desquamation) and desmosomal degradation. These enzymes are therefore of interest in the treatment of conditions where the underlying aetiology indicates that assisting the processes of desmosomal degradation and/or desquamation would be beneficial.
  • the invention provides a composition for topical application to the skin, comprising one or more stratum corneum cathepsin-D-like enzymes.
  • stratum corneum cathepsin-D-like enzyme means a protease, or a pro-enzyme thereof, which in its active form exhibits similar substrate sensitivity and inhibitor sensitivity to cathepsin-D. More specifically, the term “stratum corneum cathepsin-D-like enzyme” means a protease, or a pro-enzyme thereof, which in its active form is inhibited by pepstatin, a specific inhibitor of aspartic proteases such as cathepsin-D.
  • a pro-enzyme is an inactive form of the enzyme which may be activated by appropriate proteolytic cleavage to give the active form.
  • Suitable stratum corneum cathepsin-D-like enzymes for use according to the present invention have apparent molecular weights, as determined by the method of gel filtration of 31kDA and 60kDa.
  • the composition comprises 0.00001 to 50% more preferably 0.001 to 20% and even more preferably 0.001 to 0.1% by weight of the composition stratum corneum thiol proteases.
  • compositions according to the invention may further comprise an additional enzyme selected from glycosidases, other proteases, lipases or similar lipid modifying enzymes, ceramidases and mixtures thereof.
  • an additional enzyme selected from glycosidases, other proteases, lipases or similar lipid modifying enzymes, ceramidases and mixtures thereof.
  • the composition comprises 0.00001 to 50%, more preferably 0.001 to 20%, even more preferably 0.001 to 0.1% by weight of the composition of the additional enzyme.
  • Stratum corneum cathepsin-D-like enzymes may be extracted from human or animal skin or callus by high salt solution
  • Recombinant stratum corneum cathepsin-D-like enzymes may also be produced by biotechnological means by the over- expression of its gene in yeast, bacteria, plant or mammalian cells.
  • Glycosidases, other proteases and lipases for inclusion in the compositions according to the invention may suitably be isolated from animal, plant, fungal or bacterial sources.
  • Typical glycosidases include neuraminidase, mannosidase, galactosidase, glucosidase, N-acetyl glucosaminidase and N- acetyl galactosaminidase.
  • neuraminidase mannosidase
  • galactosidase galactosidase
  • glucosidase N-acetyl glucosaminidase
  • N-acetyl galactosaminidase N-acetyl galactosaminidase.
  • these may be isolated from plant sources including almonds, green 'coffee bean-., and spinach, or may be obtained commercially.
  • Suitable additional proteases include bromelain, papain, chymotrypsin and chymotrypsin-like enzymes, stratum corneum chymotryptic-like enzyme, serine and cysteine cathepsin and cathepsin-like enzymes, alcalase, savinase, chymopapain, clostripain, endoproteinase Asp N, protease V.8, proteinase K, subtilisin, thermolysin, plasmin, pronase, and trypsin and trypsin-like enzyme.
  • the protease may be isolated from plant sources including the seeds of wheat, barley, maize, oilseed rape, cocoa, linseed, illipe, shea nut, palm kernal, jojoba bean, pea, green bean, broad bean, soya bean and sunflower, and olives, papaya, pineapple, coconut, tomato and figs.
  • Lipases may be isolated from plant, animal or bacterial sources. Suitable enzymes include lipolase, pancreatic lipases, phospholipases, ceramidase, aryl sulphatase, cholesterol esterase, Candida rugosa OF360 lipase, humicola sp. lipase, pseudomonas sp. lipase and Candida antarctica A and B lipases.
  • compositions according to the invention also comprise a vehicle to act as a dilutant, dispersant or carrier for the active ingredients in the composition, so as to facilitate their distribution when the composition is applied to the skin and/or hair.
  • vehicle is cosmetically and/or pharmaceutically acceptable.
  • Vehicles other than water can include liquid or solid emollients, solvents, humectants, thickeners and powders typically found in cosmetic formulations. Examples of each of these types of vehicle, which can be used singly or as mixtures of one or more vehicles, are as follows:
  • Emollients such as stearyl alcohol, glyceryl monoricinoleate, glyceryl monostearate, mink "oil, cetyl alcohol, isopropyl isostearate, stearic acid, isobutyl palmitate, isocetyl stearate, oleyl alcohol, isopropyl laurate, hexyl laurate, decyl oleate, octadecan-2-ol, isocetyl alcohol, eicosanyl alcohol, behenyl alcohol, cetyl palmitate, silicone oils such as dimethylpolysiloxane, di ⁇ n-butyl sebacate, isopropyl myristate, isopropyl palmitate, isopropyl stearate, butyl stearate, polyethylene glycol, triethylene glycol, lanolin, cocoa butter, corn oil, cotton seed oil, tallow, lard, olive oil, palm kernel oil, rap
  • Propellants such as air, propane, butane, isobutane, dimethyl ether, carbon dioxide, nitrous oxide;
  • Solvents such as squalene, squalane, ethyl alcohol, methylene chloride, isopropanol, acetone, ethylene glycol monoethyl ether, diethylene glycol monobutyl ether, diethylene glycol monoethyl ether, dimethyl sulphoxide, dimethyl formamide, tetrahydrofuran;
  • Humectants such as polyhydric alcohols including glycerol, polyalkylene glycols and alkylene polyols and their derivatives, including propylene glycol, dipropylene glycol polypropylene glycol, polyethylene glycol and derivatives thereof, sorbitol, hydroxysorbitol, 1,3-butylene glycol, 1,2, 6-hexanetriol, ethoxylated glycerol, propoxylated glycerol and mixtures thereof.
  • polyhydric alcohols including glycerol, polyalkylene glycols and alkylene polyols and their derivatives, including propylene glycol, dipropylene glycol polypropylene glycol, polyethylene glycol and derivatives thereof, sorbitol, hydroxysorbitol, 1,3-butylene glycol, 1,2, 6-hexanetriol, ethoxylated glycerol, propoxylated glycerol and mixtures thereof.
  • Powders such as chalk, talc, fullers earth, kaolin, starch, gums, colloidal silica sodium polyacrylate, tetra alkyl and/or trialkyl ary ammonium smectites,"chemically modified magnesium aluminium silicate, organically modified montmorillonite clay, hydrated aluminium silicate, fumed silica, carboxyvinyl polymer, sodium carboxymethyl cellulose, ethylene glycol monostearate.
  • the vehicle will usually form from 10 to 99.9%, preferably from 50 to 99% by weight of the emulsion, and can, in the absence of other adjuncts, form the balance of the composition.
  • composition according to the invention is an emulsion, in which case an oil or oily material will normally be present, together with an emulsifier to provide either a water-in-oil emulsion or an oil-in-water emulsion, depending largely on the average hydrophillic-lyophilic balance (HLB) of the emulsifier employed.
  • HLB hydrophillic-lyophilic balance
  • compositions according to the invention can optionally comprise one or more oils or other materials having the properties of an oil.
  • oils examples include mineral oil and vegetable oils, and oil materials, such as those already proposed herein as emollients.
  • oils or oily materials include silicone oils, both volatile and non-volatile, such as polydimethyl siloxanes.
  • the oil or oily material when present for the purposes for forming an emulsion, will normally form up to 90%, preferably from 10 to 80% by volume of the composition.
  • compositions according to the invention may also optionally comprise one or more emulsifiers, the choice of which will normally determine whether a water-in-oil or an oil-in-water emulsion is formed.
  • the chosen emulsifier or emulsifiers should normally have an average HLB value of from 1 to 6.
  • a chosen emulsifier or emulsifiers should have an average HLB value of >6.
  • suitable emulsifiers are set out below in Table 1 in which the chemical name of the emulsifiers is given together with an example of a trade name as commercially available, and the average HLB value.
  • Sorbitan trioleate Arlacel 85 1.8 Sorbitan tristearate Span 65 2.1 Glycerol monooleate Aldo MD 2.7 Glycerol monostearate Atmul 84S 2.8 Glycerol monolaurate Aldo MC 3.3 Sorbitan sesquioleate Arlacel 83 3.7 Sorbitan monooleate Arlacel 80 4.3 Sorbitan monostearate Arlacel 60 4.7 Poloxyethylene (2) stearyl ether Brij 72 4.9 Poloxyethylene sorbitol beeswax derivative G-1702 5 PEG 200 dilaurate Emerest 2622 6. .3 Sorbitan monopalmitate Arlacel 40 6. .7 Polyoxyethylene (3.5) nonyl phenol Emulgen 903 7. .8 PEG 200 monostearate Tegester PEG
  • PEG 400 monostearate Tegester PEG 400 11.9 Polyoxyethylene 10 monooleate Ethofat 0/20 12.2 Polyoxyethylene (10) stearyl ether Brij 76 12.4 Polyoxyethylene (10) cetyl ether Brij 56 12.9 Polyoxyethylene (9.3) octyl phenol Triton X-100 13.0 Polyoxyethylene (4) sorbitan monolaurate Tween 21 13.3 PEG 600 monooleate Emerest 2660 13.7 PEG 1000 dilaurate Kessco 13.9 Polyoxyethylene sorbitol lanolin derivative G-1441 14.0 Polyoxyethylene (12) lauryl ether Ethosperse LA-12 14.4 PEG 1500 dioleate Pegosperse 1500 14.6 Polyoxyethylene (14) laurate Arosurf HFL-714 14.8
  • the amount of emulsifier or mixtures thereof, to be incorporated in the composition of the invention, when appropriate is from 1 to 50%, preferably from 2 to 20% and most preferably from 2 to 10% by weight of the composition.
  • compositions of the invention can also comprise water, usually up to 80%, preferably from 5 to 80% by "volume.
  • Emulsifiers or surfactants in the form of silicone polymers may be incorporated into compositions of the present invention in place of or in addition to the optional emulsifier(s) already mentioned.
  • a particularly preferred silicone surfactant is cyclomethicone and dimethicone copolyol, such as DC 3225C Formulation Aid available from DOW CORNING.
  • the amount of silicone surfactant, when present in the composition will normally be up to 25%, preferably from 0.5 to 15% by weight of the emulsion.
  • adjuncts conventionally found in cosmetic or pharmaceutical formulations may optionally be present in the compositions according to the present invention. They include preservatives, such as para-hydroxy benzoate esters; antioxidants, such butyl hydroxy toluene; humectants, such as glycerol, sorbitol, 2-pyrrolidone-5- carboxylate, dibutylphthalate, gelatin, polyethylene glycol, preferably PEG 200-600; buffers, such as lactic acid together with a base such as triethanolamine or sodium hydroxide; surfactants, such as glycerol ethers, waxes, such as beeswax, ozokerite wax, paraffin wax; plant extracts, such as Aloe vera, cornflower, witch hazel, elderflower, cucumber; thickeners; activity enhancers; colourants; and perfumes.
  • preservatives such as para-hydroxy benzoate esters
  • antioxidants such butyl hydroxy toluene
  • compositions according to the present invention include sunscreens, hydroxy carboxylic acids and ketocarboxylic acids or esters thereof and lipids such as ceramides, pseudoceramides (synthetic ceramide-like structures) , polyol fatty acid "polyesters, sterols, phospholipids, galactosyldiacylglycerols, glycosphingolipids, fatty acids or esters thereof, and mixtures thereof.
  • Suitable sunscreens include those materials commonly used to block ultraviolet light and may include inorganic sunscreen materials, such as ultrafine titanium dioxide, or organic sunscreens such as p-aminobenzoic acid and esters thereof, ethylhexyl p-methoxycinnamate, 2-ethoxyethyl p- methoxycinnamate or butylmethoxydibenzoylmethane, and mixtures thereof. It will be appreciated that the amount of sunscreen employed will vary depending on the degree of protection re ⁇ .-ired.
  • ceramides and synthetic analogues thereof which may be employ i are disclosed in European patent application EP-A-587288 which is incorporated by reference herein.
  • Preferred ceramides have the structure.
  • R represents a linear or branched saturated or unsaturated, hydroxylated or non-hydroxylated aliphatic hydrocarbon group having from 1 to 49 carbon atoms or a subgroup (2) .
  • R represents a linear or branched, saturated or unsaturated, hydroxylated or non-hydroxylated aliphatic hydrocarbon group having from 8 to 28 carbon atoms;
  • R_., R 3 and R 5 individually represent H, a phosphate residue or a sulphate residue
  • R 4 represents H, a phosphate residue, a sulphate residue or sugar residue; a is an integer of from 1 to 49 b is an integer of from 10 to 98 m is 0 or 1
  • Y represents H or a residue of a C,. 22 fatty acid having the general structure (3)
  • Z is - OH or an epoxy oxygen x is an integer of from 0 to 20 y is an integer of from 0 to 40 and z is 0 or an integer of from 1 to 4
  • Ceramides having the general structure (l) are naturally occurring and can be isolated from a suitable plant source or from animal tissue such as pig skin or neural tissue. Ceramides can also be synthesised.
  • ceramides are ceramide-1, ceramide-2 and ceramide-3.
  • Pseudoceramides are preferably selected from pseudoceramides (i.e. synthetic ceramide like structures) having the general structure (4) :
  • B represents - 0CH 2 - or CHOH.
  • R 6 represents a linear or branched, saturated or unsaturated, hydroxylated or non-hydroxylated aliphatic hydrocarbon group having from 1 to 49 carbon atoms or the subgroup (2) .
  • y represents a linear or branched, saturated or unsaturated, hydroxylated or non-hydroxylated hydrocarbon group having from 8 to 28 carbon atoms.
  • R 8 represents H, or a subgroup - (CH 2 ) c COOH, where c is an integer of from 1 to 6, or a subgroup having the structure (5) .
  • X,, X 2 and X 3 each individually represent H, a C, .5 alkyl or a Cj- 5 hydroxyalkyl;
  • d is 0 or an integer of from 1 to 4 e is 0 or 1 n is 0 or 1 and p is 0 or l;
  • Rg represents H, a phosphate residue, a sulphate residue or a sugar residue.
  • Polyol fatty acid polyesters are fatty acid polyesters derived from any aliphatic or aromatic polyol which has at least 4 free hydroxyl groups, of which at le " ast 60% of these free hydroxyl groups are then esterified with one or more fatty acids having from 8 to 22 carbon atoms.
  • the polyol is preferably chosen from sugar polyols, which comprise mono-, di- and polysaccharides.
  • Preferred polyol fatty acid polyesters are sucrose fatty acid polyesters where the ester is derived from lauric acid or natural oils, such as palm oil, palm kernal oil, soyabean oil, coconut oil, fish oil and mixtures thereof.
  • Sterols may conveniently be selected from cholesterol, pro- vitamin D 3 , campesterol, stigmastanol, stigmasterol, 5- dihydrocholesterol, ⁇ -spinasterol, palysterol, clionasterol, ⁇ -sitosterol, stigmastenol, sargasterol, avenasterol, ergostanol, sitosterol, corbisterol, chondrillasterol, poriferasterol, haliclonaseterol, neospongosterol, fucosterol, aptostanol, Ergostadienol, ergosterol, 22-dihydroergosterol, brassicasterol, 24- methylenecholesterol , 5-dihydroergosterol , dehydroergosterol , 14-dehydroergosterol , 24- dehydroergosterol, fungisterol, cholestanol, coprostanol, Zymosterol, 7-hetochol
  • Fatty acids are preferably essential fatty acids chosen from linoleic acid, 7-linolenic acid, homo-7-linolenic acid, columbinic acid, eicosa- (n-6,9,13) -trienoic acid, arachidonic acid, ⁇ -linolenic acid, timnodonic acid, hexaenoic acid and mixtures thereof.
  • Lipids such as those described above, may conveniently be incorporated in compositions according to the invention in an amount of from 0.00001 to 50%, preferably from 0.001 to 10%, more preferably from 0.1 to 10% by weight of the composition.
  • Suitable hydroxy acids include c--hydroxy acids, ⁇ - hydroxyacids, other hydroxycarboxylic acids and mixtures thereof.
  • the hydroxy acid is chosen from ⁇ .- hydroxy acids having the general structure:
  • R. and R b are H, alkyl, aralkyl or aryl group of saturated or unsaturated, isomeric or non-isomeric, straight or branched chain or cyclic form, having 1 to 30 carbon atoms, and in addition Rj may carry F, Cl, Br, I, N, S, OH, CHO, COOH and alkoxy group having 1 to 9 carbon atoms; and mixtures thereof.
  • the alpha hydroxy acids may be present as a free acid or an ester form, or in a salt form with an organic base or an inorganic alkali.
  • the typical alkyl, aralkyl and aryl groups for R, and R 2 include methyl, ethyl, propyl, isopropyl, butyl, pentyl, octyl, lauryl, stearyl, benzyl and phenyl, etc.
  • D, DL, or L stereoisomeric forms of an alpha hydroxy acid may be employed compositions.
  • the L form is preferred.
  • alpha hydroxy acids which may be used include, but are not limited to, alpha hydroxy acetic acid (also known as “glycolic acid”) , alpha hydroxypropionic acid (also known as “lactic acid”), alpha hydroxyoctanoic acid (also known as “alpha hydroxy caprylic acid”), alpha hydroxydodecanoic acid (also known as “alpha hydroxy lauric acid”) and mixtures thereof.
  • Suitable esters include, but are not limited to, alkyl esters (for example, methyl, ethyl, propyl, perityl, hexyl, octyl esters) and mono-, di- or triglycerides, or mixtures thereof.
  • Suitable salts of alpha hydroxy acids include but are not limited to sodium, potassium, ammonium, triethanolamine, calcium, lithium salts.
  • the salts may be obtained commercially or they may be prepared by methods known in the art, e.g., neutralizing an alpha hydroxy acid with a suitable base, such as hydroxide bases of ammonium, potassium, sodium.
  • a mixture of alpha hydroxy acids may be employed.
  • a suitable mixture comprises lactic acid, alpha hydroxy octanoic acid and alpha hydroxy lauric acid.
  • compositions according to the invention contain at least 60% of an alpha hydroxy acid in L- configuration, by weight of total alpha hydroxy acid.
  • the alpha hydroxy acid is suitably present in an amount of from 0.001% to 70%, preferably from 0.1% to 20%, most preferably from 1% to_JL0% by weight of the composition.
  • the keto acids can be chosen from ⁇ -keto acids, ⁇ -keto acids and mixtures thereof.
  • a particularly preferred ⁇ .- keto acid is 2-keto octanoic acid.
  • compositions according to the invention may also include chelating agents, particularly those having high affinity with zinc and/or magnesium ions.
  • Suitable chelating agents may conveniently be selected from aminocarboxylic acids or salts thereof, polyphosphoric acids or salts thereof, diphosphonic acids, salts of diphosphonic acids, tertiary amines, aminophosphonic acids, iminodiacetic acid derivatives, azines, hydroxyquinolines, and amino acid esters.
  • Suitable chelating agents include but are not limited to ethylene diamine tetraacetic acid, a salt of ethylene diamine tetraacetic acid, sodium pyrophosphate, sodium tripolyphosphate, 8 -hydroxyquinoline, DL- (Methylene) dinitrolo tetra acetic acids, trans-decahydronaphthylene-trans-2, 3-bis-iminodiacetic, aminophenyl ethylene diphosphonic acid, ethylene-bis-N,Nl- (2, 6-carboxyl) piperdine, adenosine triphosphate, L- cysteine methyl ester and 8-hydroxyquinoline.
  • Preferred chelating agents are EDTA and/or pyrophosphate, and/or 8-hydroxy quinoline due to their ready availability, excellent performance, relatively low cost, and safety in use.
  • the chelating agent is employed in the inventive compositions in an amount effective to enhance the activity of the enzyme. It will be appreciated that the precise amount will depend on the particular chelating agent used. Typically, the amount is in the range of 0.1 to 2%, preferably from 0.2 to 2% by weight of the composition.
  • compositions according to the invention are useful in treating or alleviating conditions of the skin which are characterised by hyperkeratinisation, decreased rate of desquamation or abnormal desmosomal formation.
  • the invention provides the cosmetic or pharmaceutical use of a composition comprising one or more stratum corneum cathepsin-D-like enzymes, particularly in the treatment of conditions where the underlying aetiology indicates that assisting desquamation and/or desmosomal degradation would be beneficial.
  • the invention further provides a method of treating skin comprising topically administering thereto a composition comprising one or more stratum corneum cathepsin-D-like enzymes.
  • compositions according to the invention will primarily be of use in the treatment of established symptoms although prophylaxis is not excluded.
  • Compositions according to the invention are of use in treating or preventing diseases of the skin such as psoriasis, ichthyosis and acne.
  • Compositions according to the invention are of particular interest in treating dry and/or flaky skin and in smoothing and enhancing the quality of skin.
  • the compositions may also be used to alleviate dandruff.
  • the amount of the composition and the frequency of its application to the skin will depend on the condition of the patient.
  • a small quantity of the composition for example from 1 to 5ml, is applied to areas of the skin or scalp, from a suitable container or applicator and, if necessary, it is then spread over and/or rubbed into the skin or scalp using the hand or fingers or a suitable device.
  • topical skin treatment compositions according to the invention may be formulated in conventional manner using one or more cosmetically and/or pharmaceutically acceptable carriers or excipients.
  • the topical compositions of the invention may suitably be formulated as a lotion having a viscosity of from 4,000 to 10,000 mPas, a fluid cream having a viscosity of from 10,000 to 20,000 mPas or a cream having a viscosity of from 20,000 to 100,000 mPas, or above.
  • the composition can be packaged in a suitable container to suit its viscosity and intended use by the consumer.
  • a lotion or fluid cream can be packaged in a bottle or a roll-ball applicator or a propellant-driven aerosol device or a container fitted with a pump suitable for finger operation.
  • composition When the composition is a cream, it can simply be stored in a non-deformable bottle or squeeze container, such as a tube or a lidded jar.
  • a non-deformable bottle or squeeze container such as a tube or a lidded jar.
  • the composition may be used for general lotions and creams, leave-on- creams, wash-off cleansers, face masks shampoos and bath oils.
  • the invention accordingly also provides a closed container containing an acceptable composition as herein defined.
  • Stratum corneum cathepsin-D-like activity was derived from either human plantar or freeze scraped pig stratum corneum.
  • the tissues were extracted in IM sodium chloride in 0.05M sodium acetate pH6, 0.1% (v/v) Triton X-100 at 4°C.
  • the extracts were fractionated by size using a Superose 12 gel filtration column with a buffer of 0.02M sodium acetate pH6 containing IM sodium chloride.
  • Cathepsin-D-like activity was determined by a modification of the haemoglobin (hb) hydrolysis assay described Barret,
  • Haemoglobin (Hb) hydrolysis is defined as the * amount of cathepsin-D-like activity which produces 1000 dpm of TCA soluble material. Inhibition profile
  • concentrations of inhibitors used were l ⁇ M pepstatin, lO ⁇ M leupeptin, lO ⁇ M chymostatin, l ⁇ M aprotinin, 2mM PMSF, l ⁇ M E64, 5mM EDTA and lOO ⁇ M zinc sulphate.
  • Cathepsin-D-like specificity was shown by the almost total inhibition of activity by pepstatin.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Birds (AREA)
  • Cosmetics (AREA)

Abstract

Composition destinée à être appliquée localement sur la peau pour réduire ou empêcher la desquamation, les pellicules ou l'acné et comprenant une ou plusieurs enzymes semblables à la cathépsine D de la couche cornée. De plus, la composition peut comprendre une deuxième enzyme sélectionnée parmi les glycosidases, les protéases, les lipases et des mélanges de celles-ci. D'autres principes actifs éventuels comprennent des filtres solaires, des lipides, des acides hydroxy carboxyliques et cétocarboxyliques.
EP94926925A 1993-09-15 1994-09-08 Procede et composition de soin pour la peau Withdrawn EP0719132A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB939319103A GB9319103D0 (en) 1993-09-15 1993-09-15 Skin care method & composition
GB9319103 1993-09-15
PCT/EP1994/003000 WO1995007687A1 (fr) 1993-09-15 1994-09-08 Procede et composition de soin pour la peau

Publications (1)

Publication Number Publication Date
EP0719132A1 true EP0719132A1 (fr) 1996-07-03

Family

ID=10742041

Family Applications (1)

Application Number Title Priority Date Filing Date
EP94926925A Withdrawn EP0719132A1 (fr) 1993-09-15 1994-09-08 Procede et composition de soin pour la peau

Country Status (7)

Country Link
EP (1) EP0719132A1 (fr)
AU (1) AU7656794A (fr)
CA (1) CA2166531A1 (fr)
GB (1) GB9319103D0 (fr)
NZ (1) NZ273328A (fr)
WO (1) WO1995007687A1 (fr)
ZA (2) ZA947145B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19600480A1 (de) * 1996-01-09 1997-07-10 Beiersdorf Ag Verwendung von Serin-Proteinasen gegen Akne und entzündete Comedonen
DE19824073A1 (de) * 1998-05-29 1999-12-02 Beiersdorf Ag Kosmetische und dermatologische Zubereitungen mit einem wirksamen Gehalt an immobilisierten oder freien Lipasen, die die Viskosität von Hautfett beeinflussen
TWI395593B (zh) 2008-03-06 2013-05-11 Halozyme Inc 可活化的基質降解酵素之活體內暫時性控制
GB201305023D0 (en) 2013-03-19 2013-05-01 Biocant Associa O De Transfer Ncia De Tecnologia Aspartic proteases

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5920211A (ja) * 1982-07-27 1984-02-01 Taizo Ayukawa パツク組成物
GB9207280D0 (en) * 1992-04-02 1992-05-13 Unilever Plc Skin care method and composition
GB9207288D0 (en) * 1992-04-02 1992-05-13 Unilever Plc Cosmetic composition

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9507687A1 *

Also Published As

Publication number Publication date
NZ273328A (en) 1996-08-27
GB9319103D0 (en) 1993-11-03
AU7656794A (en) 1995-04-03
ZA947139B (en) 1996-03-15
ZA947145B (en) 1996-03-15
CA2166531A1 (fr) 1995-03-23
WO1995007687A1 (fr) 1995-03-23

Similar Documents

Publication Publication Date Title
US5665366A (en) Skin care method and composition
US5545402A (en) Skin care method and composition
US5554366A (en) Skin care method and composition
US5439935A (en) Skin care method and composition
US9381146B2 (en) Skin conditioner
CA2323451C (fr) Creme revitalisante
JPWO1999045900A1 (ja) 皮膚健全化剤
EP2051690B1 (fr) Emploi de dérivés de c-glycoside en tant que principes actifs favorisant la desquamation
US7999008B2 (en) Urea compounds that promote desquamation
KR100798607B1 (ko) 단백질과 효소 저해물질을 함유하는 미용 조성물
WO1995007687A1 (fr) Procede et composition de soin pour la peau
NZ329890A (en) Cosmetic topical composition containing a ceramide derivative
WO1995005159A1 (fr) Hydroxyalcanoates acyles et leurs utilisations
AU2006203098B2 (en) Skin conditioner

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19951219

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): CH DE ES FR GB IT LI NL SE

17Q First examination report despatched

Effective date: 19970926

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19980207